Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab

Bookmark and Share
Published: 14 Jul 2020
Views: 335
Prof Scott Tykodi - University of Washington, Seattle, USA

Prof Scott Tykodi speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

He outlines the background and methods of this study, which assessed the association of RNA-sequencing–based gene expression signatures and DNA alterations with response or resistance to pembrolizumab in patients with advanced renal cell carcinoma (RCC) treated in the KEYNOTE-427 trial.

Prof Tykodi concludes that RNA-sequencing–based, T-cell–inflamed gene expression profiles was associated with overall response rate in patients with cell renal cell carcinoma (RCC) receiving first-line pembrolizumab.